Sino Biopharmaceutical Limited: Primary Myelofibrosis trials
The registry lists 10 Primary Myelofibrosis studies with Sino Biopharmaceutical Limited as lead sponsor. 3 are open to participants now and 0 have results posted.
Phase 1 9Phase 2 3(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of TQ05105 Tablets in Subjects With Intermediate/High-risk MyelofibrosisRecruitingNCT07551427Phase 2
- To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Hepatic Impairment SubjectsRecruitingNCT07480824Phase 1
- A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF)RecruitingNCT06122831Phase 1/2
- QT Interval/Corrected QT Interval （QT/QTc） Clinical Study to Evaluate the Cardiac Safety of TQ05105 Tablets in Healthy ParticipantsActive, not recruitingNCT07708272Phase 1
- Study to Evaluate the Effect of Rabeprazole Sodium Enteric-coated Tablets on the Pharmacokinetics of TQ05105 TabletsActive, not recruitingNCT07608666Phase 1
- To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Renal Impairment SubjectsCompletedNCT06598956Phase 1
- TQ05105 Tablet for Myelofibrosis Treatment in Ruxolitinib-Resistant or Intolerant PatientsTerminatedNCT06388759Phase 1
- A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF)TerminatedNCT06245941Phase 1/2
- A Study to Evaluate Drug-Drug Interaction of TQ05105 TabletsCompletedNCT06024915Phase 1
- To Evaluate the Effect of Food on the Pharmacokinetics of TQ05105 Tablets in Healthy Adult SubjectsCompletedNCT05982106Phase 1